PriceTargets.com logo

Hologic - HOLX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $89.91
  • Forecasted Upside: 15.21%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$78.04 As of 11/20/2024 01:00 AM ET
▼ -0.53 (-0.67%)

This chart shows the closing price for HOLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hologic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HOLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HOLX

Analyst Price Target is $89.91
▲ +15.21% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Hologic in the last 3 months. The average price target is $89.91, with a high forecast of $95.00 and a low forecast of $82.00. The average price target represents a 15.21% upside from the last price of $78.04.

This chart shows the closing price for HOLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 investment analysts is to moderate buy stock in Hologic. This rating has held steady since April 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/5/2024UBS GroupBoost TargetNeutral ➝ Neutral$84.00 ➝ $90.00
11/5/2024MizuhoLower TargetOutperform ➝ Outperform$90.00 ➝ $87.00
11/5/2024Raymond JamesBoost TargetOutperform ➝ Outperform$93.00 ➝ $95.00
11/5/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$86.00 ➝ $89.00
11/5/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$92.00 ➝ $94.00
10/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
10/8/2024Leerink PartnersLower TargetOutperform ➝ Outperform$95.00 ➝ $90.00
10/4/2024MizuhoBoost TargetOutperform ➝ Outperform$85.00 ➝ $90.00
10/1/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$78.00 ➝ $82.00
10/1/2024CitigroupDowngradeBuy ➝ Neutral$95.00 ➝ $85.00
9/17/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
8/16/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$82.00 ➝ $82.00
7/30/2024StephensReiterated RatingOverweight ➝ Overweight$92.00 ➝ $92.00
7/30/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$76.00 ➝ $78.00
7/30/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$91.00 ➝ $95.00
7/30/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$81.00 ➝ $82.00
7/30/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
7/2/2024Evercore ISILower TargetIn-Line ➝ In-Line$78.00 ➝ $76.00
6/27/2024StephensInitiated CoverageOverweight$87.00
5/9/2024ArgusBoost TargetBuy ➝ Buy$89.00 ➝ $95.00
5/3/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$85.00 ➝ $91.00
5/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$90.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$90.00
4/4/2024Evercore ISIBoost TargetIn-Line ➝ In-Line$76.00 ➝ $78.00
4/3/2024CitigroupUpgradeNeutral ➝ Buy$80.00 ➝ $95.00
2/2/2024UBS GroupBoost TargetNeutral ➝ Neutral$78.00 ➝ $79.00
2/2/2024William BlairReiterated RatingOutperform
2/2/2024Raymond JamesBoost TargetOutperform ➝ Outperform$85.00 ➝ $88.00
2/2/2024Needham & Company LLCBoost TargetBuy ➝ Buy$83.00 ➝ $90.00
1/8/2024William BlairReiterated RatingOutperform
11/16/2023UBS GroupLower TargetNeutral ➝ Neutral$91.00 ➝ $78.00
11/13/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$86.00 ➝ $82.00
11/10/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$74.00 ➝ $72.00
11/10/2023William BlairReiterated RatingOutperform
10/26/2023Needham & Company LLCLower TargetBuy ➝ Buy$95.00 ➝ $83.00
10/18/2023Raymond JamesLower TargetOutperform ➝ Outperform$95.00 ➝ $85.00
10/5/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$81.00 ➝ $78.00
8/1/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$86.00
8/1/2023CitigroupLower TargetNeutral ➝ Neutral$90.00 ➝ $85.00
8/1/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$95.00
8/1/2023Raymond JamesLower TargetOutperform ➝ Outperform$100.00 ➝ $95.00
8/1/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$87.00 ➝ $85.00
8/1/2023Bank of AmericaLower TargetNeutral ➝ Neutral$94.00 ➝ $86.00
7/14/2023Needham & Company LLCUpgradeHold ➝ Buy$95.00
5/2/2023JPMorgan Chase & Co.Boost Target$95.00 ➝ $105.00
5/2/2023Raymond JamesBoost Target$95.00 ➝ $100.00
5/2/2023MizuhoBoost Target$92.00 ➝ $95.00
5/2/2023CitigroupBoost Target$85.00 ➝ $90.00
4/18/2023MizuhoBoost Target$90.00 ➝ $92.00
2/3/2023Morgan StanleyBoost TargetEqual Weight$74.00 ➝ $81.00
2/2/2023JPMorgan Chase & Co.Boost TargetOverweight$90.00 ➝ $95.00
2/2/2023Leerink PartnersBoost TargetOutperform$90.00 ➝ $93.00
2/2/2023CowenBoost TargetOutperform$86.00 ➝ $95.00
2/2/2023Raymond JamesBoost TargetOutperform$80.00 ➝ $95.00
2/2/2023CitigroupBoost TargetNeutral$75.00 ➝ $85.00
1/24/2023MizuhoBoost TargetBuy$77.00 ➝ $90.00
1/12/2023Leerink PartnersBoost TargetOutperform$85.00 ➝ $90.00
1/10/2023Wells Fargo & CompanyBoost TargetEqual Weight$75.00 ➝ $80.00
1/6/2023Leerink PartnersBoost TargetOutperform$78.00 ➝ $85.00
12/6/2022Royal Bank of CanadaInitiated CoverageSector Perform$75.00
11/1/2022William BlairReiterated RatingOutperform
11/1/2022CowenLower TargetOutperform$88.00 ➝ $86.00
11/1/2022Evercore ISIBoost TargetIn-Line$65.00 ➝ $70.00
11/1/2022Morgan StanleyBoost TargetEqual Weight$68.00 ➝ $74.00
11/1/2022CowenLower TargetOutperform$88.00 ➝ $86.00
11/1/2022MizuhoBoost TargetBuy$75.00 ➝ $77.00
10/25/2022Morgan StanleyLower TargetEqual Weight$70.00 ➝ $68.00
10/12/2022MizuhoInitiated CoverageBuy$75.00
7/28/2022Morgan StanleyLower TargetEqual Weight$72.00 ➝ $70.00
7/20/2022UBS GroupInitiated CoverageNeutral$73.00
7/20/2022Bank of AmericaDowngradeBuy ➝ Neutral$81.00 ➝ $75.00
7/18/2022BTIG ResearchDowngradeBuy ➝ Neutral
5/17/2022Leerink PartnersBoost TargetOutperform$85.00
4/28/2022CitigroupLower Target$78.00 ➝ $75.00
4/25/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$90.00 ➝ $75.00
2/3/2022Morgan StanleyLower TargetEqual Weight$76.00 ➝ $75.00
2/3/2022Wells Fargo & CompanyLower TargetOverweight$95.00 ➝ $90.00
2/3/2022Raymond JamesLower TargetOutperform$88.00 ➝ $84.00
12/15/2021CitigroupDowngradeBuy ➝ Neutral$85.00 ➝ $78.00
12/14/2021Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$90.00 ➝ $95.00
11/2/2021Morgan StanleyBoost TargetEqual Weight$75.00 ➝ $76.00
11/2/2021William BlairReiterated RatingOutperform
10/22/2021Leerink PartnersReiterated RatingOutperform
10/14/2021Redburn PartnersInitiated CoverageNeutral
8/3/2021Raymond JamesBoost TargetOutperform$78.00 ➝ $88.00
7/30/2021William BlairReiterated RatingOutperform
7/30/2021Morgan StanleyLower TargetEqual Weight$77.00 ➝ $75.00
7/29/2021Jefferies Financial GroupInitiated CoverageBuy$95.00
7/6/2021Evercore ISIUpgradeIn-Line ➝ Outperform$78.00
4/30/2021Morgan StanleyLower TargetEqual Weight$84.00 ➝ $77.00
4/29/2021CitigroupLower Target$90.00 ➝ $80.00
4/29/2021Leerink PartnersLower TargetOutperform$94.00 ➝ $85.00
4/5/2021Jefferies Financial GroupBoost TargetBuy$106.00 ➝ $110.00
3/1/2021Robert W. BairdBoost TargetBuy$84.00 ➝ $91.00
2/22/2021Robert W. BairdReiterated RatingBuy$84.00 ➝ $91.00
2/22/2021BTIG ResearchBoost TargetBuy$84.00 ➝ $91.00
1/28/2021Wells Fargo & CompanyBoost TargetOverweight$90.00 ➝ $95.00
1/6/2021Raymond JamesReiterated RatingBuy
12/15/2020Morgan StanleyBoost TargetEqual Weight$80.00 ➝ $84.00
12/8/2020ArgusBoost Target$85.00 ➝ $100.00
11/20/2020Needham & Company LLCDowngradeBuy ➝ Hold
11/9/2020Morgan StanleyBoost TargetEqual Weight$68.00 ➝ $80.00
11/5/2020Jefferies Financial GroupBoost Target$80.00 ➝ $98.00
11/5/2020Smith Barney CitigroupBoost Target$90.00 ➝ $85.00
11/5/2020UBS GroupBoost TargetNeutral$77.00 ➝ $81.00
11/5/2020JPMorgan Chase & Co.Boost TargetOverweight$75.00 ➝ $85.00
11/5/2020Wells Fargo & CompanyBoost TargetOverweight$80.00 ➝ $90.00
11/5/2020Raymond JamesBoost TargetOutperform$75.00 ➝ $86.00
11/5/2020Leerink PartnersBoost TargetOutperform$80.00 ➝ $94.00
11/5/2020Needham & Company LLCBoost TargetBuy$78.00 ➝ $88.00
8/26/2020Needham & Company LLCReiterated RatingBuy$78.00
7/31/2020Morgan StanleyBoost TargetEqual Weight$55.00 ➝ $68.00
7/30/2020Wells Fargo & CompanyBoost TargetOverweight$63.00 ➝ $80.00
7/30/2020Raymond JamesBoost TargetOutperform$68.00 ➝ $78.00
7/30/2020CitigroupBoost TargetPositive ➝ Buy$63.00 ➝ $85.00
7/30/2020Leerink PartnersBoost TargetOutperform$66.00 ➝ $80.00
7/30/2020Needham & Company LLCBoost TargetBuy$64.00 ➝ $78.00
7/29/2020BTIG ResearchReiterated RatingBuy$63.00 ➝ $84.00
7/27/2020William BlairReiterated RatingOutperform
7/23/2020Raymond JamesBoost TargetOutperform$62.00 ➝ $68.00
7/15/2020Leerink PartnersBoost TargetOutperform$62.00 ➝ $66.00
7/1/2020Needham & Company LLCInitiated CoverageBuy$60.00 ➝ $64.00
6/30/2020CowenUpgradeMarket Perform ➝ Outperform$64.00
6/26/2020BTIG ResearchReiterated RatingBuy$60.00
6/16/2020BTIG ResearchBoost TargetBuy$54.00 ➝ $60.00
6/10/2020Needham & Company LLCReiterated RatingBuy
6/9/2020Morgan StanleyBoost TargetEqual Weight$53.00 ➝ $55.00
6/3/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$62.00
6/2/2020Needham & Company LLCInitiated CoverageBuy$60.00
4/30/2020JPMorgan Chase & Co.Boost TargetOverweight$45.00 ➝ $55.00
4/30/2020Morgan StanleyBoost TargetEqual Weight$40.00 ➝ $53.00
4/30/2020Wells Fargo & CompanyBoost TargetOverweight$48.00 ➝ $60.00
4/30/2020BTIG ResearchBoost TargetBuy$46.00 ➝ $54.00
4/30/2020Leerink PartnersUpgradeMarket Perform ➝ Outperform$41.00 ➝ $62.00
4/30/2020Needham & Company LLCBoost TargetBuy$52.00 ➝ $60.00
4/28/2020UBS GroupLower TargetNeutral$58.00 ➝ $52.00
4/19/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight
4/8/2020Leerink PartnersLower TargetMarket Perform$57.00 ➝ $41.00
4/8/2020Stifel NicolausLower TargetHold$52.00 ➝ $45.00
4/8/2020William BlairReiterated RatingOutperform
4/7/2020BTIG ResearchReiterated RatingPositive ➝ Buy$54.00 ➝ $46.00
4/7/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$48.00
4/2/2020Needham & Company LLCUpgradeBuy$62.00 ➝ $52.00
3/27/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$53.00 ➝ $40.00
3/26/2020BarclaysLower TargetEqual Weight$51.00 ➝ $43.00
3/17/2020JPMorgan Chase & Co.Lower TargetOverweight$60.00 ➝ $50.00
1/30/2020Piper SandlerBoost Target$58.00 ➝ $61.00
1/30/2020BTIG ResearchReiterated RatingBuy$54.00
1/13/2020BarclaysBoost TargetEqual Weight$50.00 ➝ $51.00
1/13/2020Needham & Company LLCBoost TargetBuy$57.00 ➝ $62.00
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$57.00
1/6/2020CitigroupInitiated CoverageBuy$60.00
1/2/2020Morgan StanleyDowngradeEqual Weight ➝ Underweight
12/17/2019Morgan StanleyBoost TargetUnderweight$45.00 ➝ $50.00
12/13/2019Stifel NicolausBoost TargetHold$48.00 ➝ $52.00
11/21/2019William BlairReiterated RatingBuy
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.91 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 25 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 21 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 21 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 28 very positive mentions
  • 23 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 23 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 24 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 32 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 32 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Hologic logo
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Read More

Today's Range

Now: $78.04
Low: $77.60
High: $78.49

50 Day Range

MA: $80.52
Low: $77.54
High: $83.72

52 Week Range

Now: $78.04
Low: $67.59
High: $84.67

Volume

1,298,044 shs

Average Volume

1,590,061 shs

Market Capitalization

$18.13 billion

P/E Ratio

23.44

Dividend Yield

N/A

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Hologic?

The following Wall Street research analysts have issued reports on Hologic in the last year: Argus, Citigroup Inc., Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Mizuho, Needham & Company LLC, Raymond James, Royal Bank of Canada, Stephens, StockNews.com, UBS Group AG, and William Blair.
View the latest analyst ratings for HOLX.

What is the current price target for Hologic?

0 Wall Street analysts have set twelve-month price targets for Hologic in the last year. Their average twelve-month price target is $89.91, suggesting a possible upside of 15.2%. Raymond James has the highest price target set, predicting HOLX will reach $95.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $82.00 for Hologic in the next year.
View the latest price targets for HOLX.

What is the current consensus analyst rating for Hologic?

Hologic currently has 4 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for HOLX.

What other companies compete with Hologic?

Other companies that are similar to Hologic include Qiagen, Becton, Dickinson and Company, Edwards Lifesciences, ResMed and IDEXX Laboratories. Learn More about companies similar to Hologic.

How do I contact Hologic's investor relations team?

Hologic's physical mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider's listed phone number is (508) 263-2900 and its investor relations email address is [email protected]. The official website for Hologic is www.hologic.com. Learn More about contacing Hologic investor relations.